312 related articles for article (PubMed ID: 32517716)
21. Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.
Horinouchi H; Atagi S; Oizumi S; Ohashi K; Kato T; Kozuki T; Seike M; Sone T; Sobue T; Tokito T; Harada H; Maeda T; Mio T; Shirosaka I; Hattori K; Shin E; Murakami H
Cancer Med; 2020 Sep; 9(18):6597-6608. PubMed ID: 32730697
[TBL] [Abstract][Full Text] [Related]
22. Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235.
Bazan JG; Duan F; Snyder BS; Horng D; Graves EE; Siegel BA; Machtay M; Loo BW
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):17-24. PubMed ID: 27645692
[TBL] [Abstract][Full Text] [Related]
23. Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses.
Ni J; Li G; Yang X; Chu L; Wang J; Li Y; Zou L; Li Y; Xie C; Zhu Z
Radiat Oncol; 2019 Mar; 14(1):44. PubMed ID: 30866974
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
Darling GE; Li F; Patsios D; Massey C; Wallis AG; Coate L; Keshavjee S; Pierre A; De Perrot M; Yasufuku K; Cypel M; Waddell T
Eur J Cardiothorac Surg; 2015 Nov; 48(5):684-90; discussion 690. PubMed ID: 25567960
[TBL] [Abstract][Full Text] [Related]
25. Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
Nakamura M; Kageyama SI; Niho S; Okumura M; Hojo H; Motegi A; Nakamura N; Zenda S; Yoh K; Goto K; Akimoto T
Clin Lung Cancer; 2019 May; 20(3):e256-e264. PubMed ID: 30926356
[TBL] [Abstract][Full Text] [Related]
26. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
[TBL] [Abstract][Full Text] [Related]
27. Superior sulcus non small cell lung carcinoma: retrospective analysis of 42 patients.
Truntzer P; Antoni DN; Santelmo N; Schumacher C; Falcoz PE; Quoix E; Steib JP; Massard G; Noël G
Radiat Oncol; 2014 Nov; 9():259. PubMed ID: 25424982
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer.
Parks J; Kloecker G; Woo S; Dunlap NE
Am J Clin Oncol; 2016 Apr; 39(2):147-53. PubMed ID: 24457534
[TBL] [Abstract][Full Text] [Related]
29. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
30. Eight cases of salvage pulmonary resection for residual disease or isolated local recurrence detected after definitive chemoradiotherapy for N2 Stage-IIIA lung cancer.
Sawada S; Suehisa H; Ueno T; Yamashita M
Asian J Surg; 2017 Apr; 40(2):95-99. PubMed ID: 26362070
[TBL] [Abstract][Full Text] [Related]
31. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
32. Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.
Kilburn JM; Lester SC; Lucas JT; Soike MH; Blackstock AW; Kearns WT; Hinson WH; Miller AA; Petty WJ; Munley MT; Urbanic JJ
J Thorac Oncol; 2014 Apr; 9(4):572-6. PubMed ID: 24736084
[TBL] [Abstract][Full Text] [Related]
33. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
34. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy.
Winther-Larsen A; Hoffmann L; Moeller DS; Khalil AA; Knap MM
Acta Oncol; 2015; 54(9):1574-81. PubMed ID: 26203924
[TBL] [Abstract][Full Text] [Related]
36. Should salvage surgery be considered for local recurrence after definitive chemoradiation in locally advanced non-small cell lung cancer?
Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
J Cardiothorac Surg; 2016 Jan; 11():9. PubMed ID: 26781697
[TBL] [Abstract][Full Text] [Related]
37. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
[TBL] [Abstract][Full Text] [Related]
38. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
[TBL] [Abstract][Full Text] [Related]
39. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
40. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
Koshy M; Malik R; Spiotto M; Mahmood U; Rusthoven CG; Sher DJ
Lung Cancer; 2017 Jun; 108():222-227. PubMed ID: 28625640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
